Group 1 - The medical health ETF, Taikang (159760), is experiencing a tight market with frequent premiums, while the index it tracks, the National Certificate Public Health and Medical Health Index (980016), has increased by 0.11% [1] - Key stocks in the index include Huitai Medical (688617) up 3.63%, Tonghua Dongbao (600867) up 2.65%, Yirui Technology (688301) up 1.80%, and others showing positive performance [1] - The National Medical Products Administration held a meeting on June 20 to discuss measures supporting the innovation and development of high-end medical devices, approving initiatives for optimizing lifecycle regulation [1] Group 2 - The National Certificate Public Health and Medical Health Index reflects the market performance of listed companies in the public health and medical health industry in the A-share market [2] - The index focuses on companies in prevention, testing, and treatment sectors, which are seen as having significant potential for AI technology applications in proactive health management [2] - As of May 30, 2025, the top ten weighted stocks in the index account for 52.46%, including companies like Heng Rui Medicine (600276) and WuXi AppTec (603259) [2]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1]. Core Insights - The GLP-1 drug market is expected to see significant growth, with projections indicating that the market size for GLP-1 drugs in the U.S. for diabetes and obesity could reach approximately $100 billion by 2030 [4][5]. - The report identifies three key potential growth areas within the GLP-1 sector: fat loss and muscle gain, oral formulations, and ultra-long-acting formulations [5]. Summary by Sections Part 1: GLP-1 Drug Market Outlook - The GLP-1 receptor agonists (RA) have shown strong performance in glucose control and weight loss, with the drug semaglutide projected to achieve sales of $29.3 billion in 2024, closely competing with the leading drug, K drug, which is expected to generate $29.5 billion [5][4]. - The global market for GLP-1 RAs is anticipated to reach $100 billion by 2030, driven by expanding indications and accumulating clinical data [5]. Part 2: Trend One - Opportunities in Fat Loss and Muscle Gain - GLP-1 RAs have demonstrated effectiveness in fat loss, but the issue of muscle loss needs to be addressed. Pharmaceutical companies are increasingly focusing on the fat loss and muscle gain segment, with the ActRII pathway being a hot research direction [5][4]. - Future fat loss and muscle gain drugs are expected to complement GLP-1 drugs, enhancing their market position and lifecycle [5]. Part 3: Trend Two - Oral GLP-1 Drugs - Oral formulations of GLP-1 drugs offer significant convenience over injections, improving patient compliance. Novo Nordisk leads in this area with its oral semaglutide, while Eli Lilly's Orforglipron is progressing rapidly in clinical trials [5][4]. Part 4: Trend Three - Ultra-Long-Acting GLP-1 Drugs - Ultra-long-acting GLP-1 RAs are designed to extend the duration of action and reduce dosing frequency, significantly enhancing patient adherence. Some investigational products may allow for administration every four weeks [5][4]. Part 5: Investment Recommendations - The report suggests focusing on investment opportunities in the fat loss and muscle gain segment, oral formulations, and ultra-long-acting formulations. Specific companies to watch include: - Fat loss and muscle gain: Likai Pharmaceutical - Oral formulations: Heng Rui Medicine, East China Pharmaceutical, and Galenica - Ultra-long-acting formulations: Zhongsheng Pharmaceutical, Ganli Pharmaceutical, and Tonghua Dongbao [5].

Core Viewpoint - The controlling shareholder, Dongbao Industrial Group Co., Ltd., has increased its stake in Tonghua Dongbao Pharmaceutical Co., Ltd. from 31.06% to 32.07%, indicating confidence in the company's future development and value recognition [4][8]. Summary by Relevant Sections Shareholding Changes - The total shareholding percentage before the change was 31.06%, and after the change, it is 32.07% [1][8]. - The increase in shareholding was achieved through a series of transactions, including a planned increase of at least 1% of the total share capital, which equates to 19,817,341 shares, and a maximum of 2%, or 39,634,681 shares, within a 12-month period starting from October 31, 2024 [4][5]. Transaction Details - From October 31, 2024, to November 15, 2024, Dongbao Group acquired 2,050,100 shares for a total amount of 17,773,752.93 yuan, representing 0.1034% of the company's total share capital [5]. - From November 16, 2024, to January 2, 2025, Dongbao Group further acquired 5,968,600 shares, increasing its shareholding percentage to 31.37% [6][8]. Share Buyback Program - The company completed its second phase of share buyback, repurchasing 23,191,245 shares, which accounted for 1.17% of the total share capital, with an average buyback price of 7.76 yuan per share [7][8]. - The buyback led to a passive increase in the shareholding percentage of Dongbao Group and its concerted actors, from 31.37% to 31.74% [8]. Regulatory Compliance - The changes in shareholding do not trigger mandatory tender offer obligations and will not result in changes to the company's controlling shareholder or actual controller [8].

证券代码：600867 证券简称：通化东宝 公告编号：2025-043 通化东宝药业股份有限公司 关于控股股东及其一致行动人权益变动触及 1% 刻度的提示性公告 控股股东东宝实业集团股份有限公司及其一致行动人保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | | ☑ | 控股股东/实控人 | | | 东宝实业集团股份有 | □ | 控股股东/实控人的一致 | ☑91220501125495588H | | 限公司 | ...

2024 年度差异化分红事项之专项法律意见书 致：通化东宝药业股份有限公司 吉林秉责律师事务所 关于通化东宝药业股份有限公司 吉林秉责律师事务所（以下简称"本所"）接受通化东宝药业股份有限公司 （以下简称"公司""通化东宝"）委托，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》（以下简称"《上市公司自律监管指引第 7 号—回购股份》"）等有关法律、法 规和其他规范性文件以及《公司章程》的规定，就公司 2024 年年度利润分配所 涉及的差异化分红（以下简称"本次差异化分红"）相关事项出具本法律意见书。 为出具本法律意见书，本所及本所律师审查了公司提供的本次差异化分红的 相关文件，就有关事项向公司进行了必要的询问。本所律师依据本法律意见书出 具日以前已经发生或存在的事实并基于对现行法律、法规和规范性文件的理解发 表法律意见。 本法律意见书仅就本次差异化分红所涉及到的法律问题发表法律意见，并不 对有关会计、审计、验资等专业事项和报告发表意见。本法律意见书中对有关审 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-042 通化东宝药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/24 | － | 2025/6/25 | 2025/6/25 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 21 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关 规定，公司存放于回购专用证券账户的股份不参 ...

吉林秉责律师事务所 关于通化东宝药业股份有限公司 致：通化东宝药业股份有限公司 吉林秉责律师事务所（以下简称"本所"）接受通化东宝药业股份有限公司 （以下简称"公司""通化东宝" ）委托，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》 （以下简称"《上市公司自律监管指引第 7 号—回购股份》"）等有关法律、法 规和其他规范性文件以及《公司章程》的规定，就公司 2024 年年度利润分配所 涉及的差异化分红（以下简称"本次差异化分红"）相关事项出具本法律意见书。 为出具本法律意见书，本所及本所律师审查了公司提供的本次差异化分红的 相关文件，就有关事项向公司进行了必要的询问。本所律师依据本法律意见书出 具日以前已经发生或存在的事实并基于对现行法律、法规和规范性文件的理解发 表法律意见。 本法律意见书仅就本次差异化分红所涉及到的法律问题发表法律意见，并不 对有关会计、审计、验资等专业事项和报告发表意见。本法律意见书中对有关审 计报告、验资报告中某些数据和结论的引述，并 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-042 通化东宝药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.25元（含税） ? 相关日期 现金红利发放 | | | | | 日 | | --- | --- | --- | --- | --- | | 股份类别 Ａ股 | 股权登记日 2025/6/24 | － | 最后交易日 2025/6/25 | 除权（息）日 2025/6/25 | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 21 日的2024年年度股东大会审议通过。 利润分配方案：公司以实施权益分派股权登记日的总股本为基数（扣除存放于 回购专用证券账户全部股份），向全体股东每 10 股派发现金红利 2.50 元（含税）。 截至本公告披露日，公司总股本 1,958,542,829 股,扣除回购专用证券账户上 已回购股份 15,077,817 股后股本数为 1,943,4 ...

Industry Overview - Gout is a chronic disease caused by purine metabolism disorders, characterized by hyperuricemia and the deposition of urate crystals in joints and tissues, leading to various clinical symptoms [1][2] - The gout medication market in China has grown significantly, with the market size increasing from 700 million yuan in 2015 to 2.2 billion yuan in 2024 [1][10] - The prevalence of hyperuricemia in China is approximately 14%, with a patient population of around 197 million, while gout prevalence ranges from 1% to 3%, affecting approximately 15.5 to 42.29 million people [6][8] Market Dynamics - The gout medication market is primarily driven by the increasing incidence of gout and hyperuricemia due to lifestyle changes and dietary habits [10] - The market is currently experiencing a contraction due to the entry of mainstream gout medications like febuxostat into centralized procurement, but future growth is expected as patient numbers rise [10] - By 2030, the gout medication market in China is projected to exceed 10 billion yuan [10] Product Classification - Gout medications are categorized into acute anti-inflammatory analgesics and long-term urate-lowering drugs, with urate-lowering drugs accounting for about 40% of the global market [2][4] - In the domestic market, traditional drugs like febuxostat and benzbromarone hold a market share of approximately 60% [2] Competitive Landscape - The industry is characterized by intense competition, with generic drugs dominating the market while innovative drugs are rapidly being developed [14] - Major players include Kangyuan Pharmaceutical, Huahai Pharmaceutical, Yipinhong, and Hengrui Medicine, which are focusing on developing new urate-lowering agents to address the limitations of existing medications [14][15] - The introduction of centralized procurement policies has pressured generic drug prices, prompting companies to shift towards high-value innovative drugs [14] Key Companies - Hengrui Medicine is developing a new urate-lowering drug, SHR4640, which has shown significant efficacy and low toxicity, with a market application expected in 2025 [15][18] - Yipinhong is working on AR882, a new urate excretion promoter, which has received FDA support for global clinical trials [15] - Tonghua Dongbao has expanded its product pipeline in the gout treatment area, with two new drugs in clinical trials [16] Development Trends - The industry is shifting from generic to innovative drug development, with URAT1 inhibitors becoming a research focus [20] - Biologics and long-acting therapies are emerging as new growth points, with products like SEL-212 expected to enhance patient compliance and market potential [21] - Personalized treatment and combination therapies are becoming key research directions, aiming to meet unmet clinical needs [22]

Group 1 - The core viewpoint of the news is that the China Securities Medicine and Health Dividend Index has shown positive performance, with a 6.35% increase over the past month and a 5.98% increase over the past three months, while year-to-date it has risen by 1.32% [2] - The index is designed to reflect the overall performance of high dividend yield securities in various industries, using a dividend yield weighted calculation method [2] - The index's top ten holdings include Mingde Biological (4.22%), Huate Dain (3.3%), Lingrui Pharmaceutical (3.21%), and others, indicating a diverse portfolio within the healthcare sector [2] Group 2 - The index is composed of stocks with a cash dividend yield greater than 0.5% and ranks within the top 80% of average daily trading volume over the past year, with annual adjustments made to the sample [3] - The index's holdings are primarily in traditional Chinese medicine (36.05%), chemical drugs (22.28%), and medical services (17.54%), showcasing a focus on various segments of the healthcare industry [2] - The index is maintained with specific rules regarding sample adjustments, including a limit on the proportion of changes and conditions for excluding stocks that do not meet the criteria [3]